David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom